Cellectis (NASDAQ:CLLS) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a research note published on Thursday. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Barclays lowered their price objective on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th.

Cellectis Price Performance

NASDAQ:CLLS opened at $1.87 on Thursday. Cellectis has a 52 week low of $1.70 and a 52 week high of $3.77. The stock’s fifty day moving average is $1.97 and its two-hundred day moving average is $2.20. The company has a market capitalization of $103.93 million, a P/E ratio of -1.44 and a beta of 3.10. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The company had revenue of $18.05 million during the quarter, compared to analysts’ expectations of $5.00 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. During the same quarter last year, the firm posted ($0.31) earnings per share. Equities analysts expect that Cellectis will post -0.46 EPS for the current year.

Hedge Funds Weigh In On Cellectis

Institutional investors have recently bought and sold shares of the company. XTX Topco Ltd acquired a new stake in shares of Cellectis during the second quarter worth about $29,000. First Affirmative Financial Network acquired a new stake in Cellectis during the 3rd quarter worth approximately $45,000. Principal Financial Group Inc. boosted its position in Cellectis by 2.9% in the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after buying an additional 12,467 shares during the period. Finally, Long Focus Capital Management LLC grew its stake in shares of Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after acquiring an additional 130,000 shares in the last quarter. 63.90% of the stock is owned by institutional investors and hedge funds.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.